ATE455559T1 - Verfahren zur immunmodulation bei tieren - Google Patents

Verfahren zur immunmodulation bei tieren

Info

Publication number
ATE455559T1
ATE455559T1 AT04714559T AT04714559T ATE455559T1 AT E455559 T1 ATE455559 T1 AT E455559T1 AT 04714559 T AT04714559 T AT 04714559T AT 04714559 T AT04714559 T AT 04714559T AT E455559 T1 ATE455559 T1 AT E455559T1
Authority
AT
Austria
Prior art keywords
animals
immune modulation
potentiation
applicant
things
Prior art date
Application number
AT04714559T
Other languages
English (en)
Inventor
Joy Campbell
Ronald Strohbehn
Eric Weaver
Barton Borg
Louis Russell
Pozo Francisco Javier Polo
John Arthington
James Quigley
Original Assignee
Lauridsen Group Inc
Campbell Joy M
Strohbehn Ronald E
Weaver Eric M
Borg Barton S
Russell Louis E
Pozo Francisco Javier Polo
Arthington John D
Quigley Iii James D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lauridsen Group Inc, Campbell Joy M, Strohbehn Ronald E, Weaver Eric M, Borg Barton S, Russell Louis E, Pozo Francisco Javier Polo, Arthington John D, Quigley Iii James D filed Critical Lauridsen Group Inc
Application granted granted Critical
Publication of ATE455559T1 publication Critical patent/ATE455559T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
AT04714559T 2003-02-25 2004-02-25 Verfahren zur immunmodulation bei tieren ATE455559T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/375,844 US20030190314A1 (en) 2001-01-30 2003-02-25 Methods and compositions of treatment for modulating the immune system of animals
PCT/US2004/005499 WO2004075988A2 (en) 2003-02-25 2004-02-25 Methods of immunomodulation in animals

Publications (1)

Publication Number Publication Date
ATE455559T1 true ATE455559T1 (de) 2010-02-15

Family

ID=32926272

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04714559T ATE455559T1 (de) 2003-02-25 2004-02-25 Verfahren zur immunmodulation bei tieren

Country Status (7)

Country Link
US (2) US20030190314A1 (de)
EP (1) EP1599227B1 (de)
AT (1) ATE455559T1 (de)
DE (1) DE602004025207D1 (de)
DK (1) DK1599227T3 (de)
ES (1) ES2340492T3 (de)
WO (1) WO2004075988A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2437095A1 (en) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for modulating the immune system of animals
BR0206869A (pt) * 2001-01-30 2007-01-02 Lauridsen Group Inc método para o tratamento de um animal sofrendo de um estado doentio de disfunção imune associado com nìveis alterados de igg ou tnf-delta, composição farmacêutica para o tratamento de distúrbios auto-imunes associados com elevados igg e/ou tnf-delta ou para a potenciação de protocolos de vacina, e método para o tratamento de estado doentio associado com disfunção imune em um animal
US20030190314A1 (en) * 2001-01-30 2003-10-09 The Lauridsen Group Methods and compositions of treatment for modulating the immune system of animals
ZA200506094B (en) * 2002-12-31 2006-11-29 Mmi Genomics Inc Compositions, methods and systems for inferring bovine traits
WO2005040400A2 (en) * 2003-10-24 2005-05-06 Mmi Genomics, Inc. Methods and systems for inferring traits to manage non-beef livestock
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7419682B2 (en) * 2004-08-30 2008-09-02 Apc, Inc. Poultry feed containing plasma
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
AR052472A1 (es) 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
EP2303291B1 (de) * 2008-05-23 2013-02-27 The Lauridsen Group, Inc. Iga und igg zur reduzierung von lungenentzündungen in einem tier
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
EP2364098B1 (de) * 2008-12-16 2016-10-12 Hill's Pet Nutrition, Inc. Antioxidationsmittelhaltige nahrungsmittelzusammensetzung für die verwendung zur förderung der antiviralen immunität bei haustieren
MX2011010633A (es) 2009-04-09 2012-01-20 Entegrion Inc Productos sanguineos deshidratados por aspersion y metodos para elaborar los mismos.
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US20110142885A1 (en) * 2009-09-16 2011-06-16 Velico Medical, Inc. Spray-dried human plasma
US8407912B2 (en) 2010-09-16 2013-04-02 Velico Medical, Inc. Spray dried human plasma
BR112013010575A2 (pt) 2010-10-29 2016-08-09 Velico Medical Inc conjunto de secagem por atomização, câmara de secagem por atomização, conjunto de cabeça de secagem por atomização, dispositivo de coleta de secagem por atomização, e, método para secar por atomização um líquido
US20140083628A1 (en) 2012-09-27 2014-03-27 Velico Medical, Inc. Spray drier assembly for automated spray drying
EP2606741B1 (de) * 2011-12-23 2014-04-16 Foodip Sarl Glycoprotein-angereicherte Zusammensetzungen als Lebensmittel- und Futterzusatz und/oder als therapeutischer Wirkstoff
US9561184B2 (en) 2014-09-19 2017-02-07 Velico Medical, Inc. Methods and systems for multi-stage drying of plasma
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
WO2016065075A1 (en) 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product
US11998861B2 (en) 2022-09-15 2024-06-04 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system
US12083447B2 (en) 2022-09-15 2024-09-10 Velico Medical, Inc. Alignment of a disposable for a spray drying plasma system
US11841189B1 (en) 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2607716A (en) * 1949-08-02 1952-08-19 Wisconsin Alumni Res Found Prophylactic compositon for scours
CA1046407A (en) * 1975-06-20 1979-01-16 Canada Packers Limited Dried particulate animal serum of reduced saline content
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4732757A (en) * 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
US4636384A (en) * 1982-06-03 1987-01-13 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
CA1260828A (en) * 1983-07-04 1989-09-26 Masakazu Iwai Therapeutic and prophylactic agent for gastrointestinal ulcers
US4623541A (en) * 1984-06-26 1986-11-18 Candian Patents And Development Limited Production of purified porcine immunoglobulins
US4816252A (en) * 1985-04-15 1989-03-28 Protein Technology, Inc. Product and process for transferring passive immunity to newborn domestic animals using ultrafiltered whey containing immunoglobulins
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5719267A (en) * 1989-10-31 1998-02-17 Ophidian Pharmaceuticals Inc. Clostridial toxin disease therapy
US5147639A (en) * 1990-06-19 1992-09-15 Ambico, Inc. Type-c rotavirus cultures and uses therefor
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
WO1994001107A1 (en) * 1992-07-08 1994-01-20 Monsanto Company Benzimidazoles for alleviating stomach ulcers in swine
US5681565A (en) * 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
US5575999A (en) * 1993-12-03 1996-11-19 Ampc, Inc. Animal feed supplement containing co-sprayed dried plasma protein and amylase
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
US5980953A (en) * 1994-10-03 1999-11-09 Stolle Milk Biologics, Inc. Anti-inflammatory factor, method of isolation, and use
US5531988A (en) * 1994-10-28 1996-07-02 Metagenics, Inc. Bacteria and immunoglobulin-containing composition for human gastrointestinal health
US5531989A (en) * 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
ES2142200B1 (es) * 1995-08-01 2000-11-01 Fichtel & Sachs Ag Disco de embrague con un disco de friccion compuesto.
DE19548221C1 (de) * 1995-12-22 1997-05-15 Biotest Pharma Gmbh Orale Anwendung von Immunglobulin-Präparationen zur Behandlung und Prophylaxe chronischer Schmerzzustände
DE69704011T2 (de) * 1996-10-09 2001-06-07 Akzo Nobel Nv Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Sweins (PRRSV)
US6004576A (en) * 1997-08-11 1999-12-21 Ampc, Inc. Granular plasma protein supplement with increased bio-efficacy
US6086878A (en) * 1997-08-21 2000-07-11 Dcv, Inc. Method of increasing muscle protein and reducing fat in animals
US20020114802A1 (en) * 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
BR0206869A (pt) * 2001-01-30 2007-01-02 Lauridsen Group Inc método para o tratamento de um animal sofrendo de um estado doentio de disfunção imune associado com nìveis alterados de igg ou tnf-delta, composição farmacêutica para o tratamento de distúrbios auto-imunes associados com elevados igg e/ou tnf-delta ou para a potenciação de protocolos de vacina, e método para o tratamento de estado doentio associado com disfunção imune em um animal
US20030190314A1 (en) * 2001-01-30 2003-10-09 The Lauridsen Group Methods and compositions of treatment for modulating the immune system of animals
US20030099633A1 (en) * 2001-10-09 2003-05-29 Campbell Joy M. Methods and compositions for treatment of immune dysfunction disorders
CA2437095A1 (en) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for modulating the immune system of animals
US20030103962A1 (en) * 2001-10-09 2003-06-05 Campbell Joy M. Methods and compositions for modulating the immune system of animals

Also Published As

Publication number Publication date
DK1599227T3 (da) 2010-05-25
EP1599227A2 (de) 2005-11-30
ES2340492T3 (es) 2010-06-04
WO2004075988A2 (en) 2004-09-10
EP1599227A4 (de) 2007-10-31
DE602004025207D1 (de) 2010-03-11
EP1599227B1 (de) 2010-01-20
WO2004075988A3 (en) 2005-04-28
US20030190314A1 (en) 2003-10-09
US20100215667A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
ATE455559T1 (de) Verfahren zur immunmodulation bei tieren
WO2005018555A3 (en) Lipid-modified immune response modifiers
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
EP2322202A3 (de) Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002078742A3 (en) Methods and compositions for treatment of immune dysfunction disorders
WO2006002976A3 (en) Canine osteoarthritis diet formulation
ITMI20020399A1 (it) Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
NO20060349L (no) Sammensetning for spedbarn eller smabarn samt anvendelse av en kilde for proteiner, en kilde for lipider, en kilde for karbohydrater og minst en probiotisk bestanddel.
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
TW200505425A (en) Compositions and method for treating infection in cattle and swine
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
AU2003270643A1 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
NO20062878L (no) Isoflavonoidpromedikamenter, terapeutiske sammensetninger derav og terapeutiske fremgangsmater som innbefatter de samme
WO2002078741A3 (en) Methods and compositions for modulating the immune system of animals
WO2005027977A3 (en) Diclofenac compositions for the treatment of skin disorders
BR0214902A (pt) Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos
WO2007036735A3 (en) Immunogenic agents againts burkholderia psudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia psuedomallei
WO2004081199A3 (en) Novel compositions and methods for the treatment of immune related disease
DE60235418D1 (de) Osteoprotegerin in Milch
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
DK1615656T3 (da) Immunmodulerende produkt opnået ud fra en Bifidobacterium-kultur og præparater indeholdende samme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties